Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. (ABOS) priced its initial public offering on Jul 2, 2021 at $16.00 per share, within its $14.00–$16.00 range, raising $160M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $618.4M. BofA Securities was lead-left underwriter, joined by Credit Suisse, Stifel and UBS. Cooley advised the company and Ropes & Gray advised the underwriters.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a disease-modifying approach to Alzheimer's disease. Its lead candidate, ACU193, is a humanized monoclonal antibody that selectively targets soluble amyloid-beta oligomers.

Status

IPO

Ticker

ABOS

Exchange

Nasdaq Global Select

Priced

Jul 2, 2021

IPO price

$16.00

Price range

$14.00–$16.00

Raised

$160M

Market cap at IPO price

$618.4M

First filed

Jun 9, 2021

Underwriters

BofA Securities, Credit Suisse, Stifel and UBS

Company counsel

Cooley

Underwriters' counsel

Ropes & Gray

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.